Result for
Topic: Vaccines and Immunity
November 9, 2020
What Pfizer’s landmark COVID vaccine results mean for the pandemic
[Press release, not peer-reviewed] Pfizer and BioNTech announced that the BNT162b2 mRNA vaccine had 90% efficacy in preventing COVID-19 in an interim analysis of an ongoing Phase 3 trial. This is the first SARS-CoV-2 vaccine trial to release Phase 3 efficacy data. The trial includes 43,538 participants, 94 of whom developed COVID-19. The press release…
November 6, 2020
Distinct Antibody Responses to SARS-CoV-2 in Children and Adults across the COVID-19 Clinical Spectrum
A study of children and adults with SARS-CoV-2 infection in New York found that there are different antibody responses between adult and pediatric populations. Cohorts of adults with COVID-19 had anti-spike IgG, IgM and IgA antibodies, as well as anti-nucleocapsid IgG antibody, while children with and without multisystem inflammatory syndrome (MIS-C) predominantly generated IgG antibodies…
November 5, 2020
Lack of Antibodies to SARS-CoV-2 in a Large Cohort of Previously Infected Persons
A total of 6.3% of 2,547 healthcare workers and first responders in the New York City and Detroit metropolitan areas with previous confirmed SARS-CoV-2 infection were seronegative. Among symptomatic persons, the proportion seronegative was largely stable between 2 weeks and 90 days following symptom onset. The proportion seronegative ranged from 0% among 79 persons previously…
November 3, 2020
Robust SARS-CoV-2-Specific T-Cell Immunity Is Maintained at 6 Months Following Primary Infection
[Pre-print, not peer-reviewed] Blood samples from 100 convalescent donors 6 months after their initial SARS-CoV-2 infection found that T-cell responses against SARS-CoV-2 were present in all donors. The median response was 50% higher among donors with an initial symptomatic infection. T-cell responses to both spike and nucleoprotein/membrane proteins strongly correlated with peak antibody levels against…
November 2, 2020
The Views of Ethnic Minority and Vulnerable Communities towards Participation in COVID-19 Vaccine Trials
A qualitative study investigating the perceptions of vaccine trials among people from ethnic minority and vulnerable communities in the UK found that while there was overall agreement that clinical research was necessary, most interviewees expressed extreme discomfort with the idea of attending a hospital for a vaccine trial. Participants highlighted concerns about fear of contracting…
Epidemiological and Clinical Findings of Short-Term Recurrence of Severe Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019 Cases: A Multicenter, Retrospective, Observational Study
A retrospective study of patients who tested positive for SARS-CoV-2 RNA after being discharged from the hospital found that short-term recurrence of positive SARS-CoV-2 RNA was common (15%), and not associated with new symptoms. Risk of onward transmission among those with recurrence was low. Of 1282 discharged patients, almost 15% retested positive during 28-day follow-up, which…
October 29, 2020
Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months
Analysis of a serology dataset from patients admitted to a New York City hospital with confirmed or suspected SARS-CoV-2 infection (n=30,082) showed that the vast majority of individuals (~92%) had moderate-to-high titers (> 1:320) of anti-spike antibodies with 90% of seroconverters making detectable neutralizing antibodies. Additionally, antibody titers from a cohort of 121 plasma donors…
Positive RT-PCR Test Results in 420 Patients Recovered From COVID-19 in Wuhan: An Observational Study
An observational study among 420 recovered COVID-19 patients in Wuhan, China suggests that recurrence rates (based on RT-PCR tests) may be lower among patients receiving a comprehensive intervention. The intervention consisted of a combination of treatments including Baduanjin execise, Chinese herbal medicine, moxibustion with acupoint application, and foot baths. Recurrence positivity rates were significantly lower…
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
A phase 2 randomized placebo-controlled trial (n=452) interim analysis found that patients who received a 2800mg dose of monoclonal antibody LY-CoV555 could reduce SARS-CoV-2 log viral load by 3.4-fold after 11 days compared to patients receiving placebo, corresponding to a 0.53 log viral load reduction (95% CI: -0.98 to -0.08). Other patients receiving a 700mg…
October 28, 2020
High Seroprevalence but Short-Lived Immune Response to SARS-CoV-2 Infection in Paris
[Pre-print, not peer reviewed] In a cohort of workers outside Paris, both the concentration (titer) and quality of antibodies against SARS-CoV-2 declined 4-8 weeks after sampling. Among a cohort of 1,847 active workers in the Paris conurbation in France, 11% were positive for IgG against SARS-CoV-2-specific protein and 9.5% had evidence of viral neutralization. After…
Previous page Next page